Drug price increases restrictions elimination provision and sale or distribution withdraw notice requirement elimination provision
Summary
SF 4250 would repeal Minnesota’s existing statutory framework that limits excessive price increases for generic and off-patent prescription drugs and requires advance notice before a manufacturer withdraws such a drug from sale or distribution in the state. The bill repeals Minnesota Statutes sections 62J.841 through 62J.846, which currently define covered drugs, prohibit certain price increases, require manufacturers to maintain a registered agent in Minnesota, and establish enforcement tools and penalties.
In place of those repealed provisions, the bill makes conforming changes to related pharmacy and health licensing statutes. It removes references to the repealed drug-price enforcement provisions from the Board of Pharmacy’s review factors and disciplinary authority, while preserving the board’s general authority over licensees and registrants. The bill also adds a new disciplinary ground for manufacturers who violate the remaining price-related provisions in sections 62J.842 or 62J.845, although those sections are themselves repealed in the bill text as introduced, indicating the bill is primarily aimed at eliminating the existing state price-control and notice regime rather than expanding it.
Impact
The bill would substantially reduce state regulation of generic and off-patent drug pricing by eliminating the statutory prohibition on excessive price increases, the related attorney general enforcement process, the private right of action tied to those provisions, and the 90-day withdrawal notice requirement. It would also remove the special registered-agent requirement for manufacturers and the associated civil penalty structure. As a result, manufacturers, wholesalers, pharmacies, and consumers would no longer be subject to the repealed Minnesota-specific drug price oversight provisions, and state agencies would lose the enforcement tools created by those sections.
Sentiment
Based on the bill title, text, and absence of recorded committee testimony or votes, the measure appears to reflect a deregulatory approach to prescription drug pricing and supply rules. The introduced language suggests support for removing restrictions on manufacturers rather than strengthening consumer protections. Because there is no transcript or vote history provided, there is no documented public debate in the materials about the bill’s merits, but the structure of the bill indicates it would likely be viewed favorably by manufacturers and industry stakeholders and less favorably by consumer advocates and those concerned about drug affordability.
Contention
The main point of contention is whether Minnesota should continue to police large price increases for generic and off-patent drugs and require advance notice before a drug is withdrawn from the market. Supporters of repeal would likely argue that the current law is burdensome, may interfere with market decisions, and could discourage distribution of low-cost drugs in the state. Opponents would likely argue that repealing these protections weakens safeguards against price gouging, reduces transparency, and could make essential medications less affordable or less available to patients, insurers, and public programs.
Changes to provisions covering prescription drug prior authorizations, transactions with group purchasers, prescription drug price transparency, health maintenance organizations, network design, coverage for immunizations, access to certain data collected, and obsolete language made.